Merck & Co. Inc. (MRK) Financial News - Merck Receives Subpoena Related to Selling Three Medicines
Merck & Co. Inc. (MRK)
Merck Receives Subpoena Related to Selling Three Medicines
2011-08-09 04:23:31
Quote: department asked for details of the marketing and
selling of Temodar, PegIntron and Intron A, from January 1, 2004
to the present “in a federal health-care investigation,†Merck
said today in a filing.
“This is the first disclosure of this matter,†Ronald
Rogers, a spokesman for Whitehouse Station, New Jersey-based
Merck, said in an e-mail. The drugmaker is cooperating with the
investigation, Rogers said, declining to provide additional
information.
brain cancer, accounted for $1.07
billion in sales last year. Intron A for cancer and PegIntron
for hepatitis C together generated $946 million in sales.
New York Stock Exchange composite trading, the
lowest price since August 2009. The shares have declined 17
percent this year.
Pfizer Inc. is the biggest U.S. drugmaker.
orenick@bloomberg.net.
rgale5@bloomberg.net ...
Open whole article (external link)
Other Financial and Stock Market News concerning Merck & Co. Inc.
Merck & Co. Inc. Stock Summary
Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
